SG Americas Securities LLC Invests $507,000 in KalVista Pharmaceuticals, Inc. $KALV

SG Americas Securities LLC purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 41,620 shares of the specialty pharmaceutical company’s stock, valued at approximately $507,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KALV. AQR Capital Management LLC acquired a new position in KalVista Pharmaceuticals during the 1st quarter valued at about $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after buying an additional 2,939 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock valued at $3,923,000 after buying an additional 12,263 shares during the period. Whalen Wealth Management Inc. bought a new position in KalVista Pharmaceuticals in the second quarter valued at approximately $124,000. Finally, Emerald Advisers LLC boosted its stake in KalVista Pharmaceuticals by 15.6% in the second quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock valued at $11,735,000 after acquiring an additional 139,859 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright increased their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Needham & Company LLC increased their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Citizens Jmp cut their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

KalVista Pharmaceuticals Trading Down 3.1%

NASDAQ KALV opened at $16.02 on Friday. KalVista Pharmaceuticals, Inc. has a one year low of $8.49 and a one year high of $19.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The firm has a market cap of $809.81 million, a P/E ratio of -4.06 and a beta of -0.14. The stock’s 50-day moving average is $15.33 and its 200-day moving average is $13.83.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.04. The business had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. Sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the sale, the chief financial officer owned 10,529 shares in the company, valued at approximately $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 31,329 shares of company stock valued at $437,371 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.